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This  study  challenges  the commonly  held  view  that the  feline  immunodeﬁciency  virus  (FIV)  infection
status  of FIV-vaccinated  cats  cannot  be  determined  using  point-of-care  antibody  test  kits  due to indis-
tinguishable  antibody  production  in  FIV-vaccinated  and  naturally  FIV-infected  cats.  The  performance  of
three commercially  available  point-of-care  antibody  test  kits  was  compared  in  a mixed  population  of  FIV-
vaccinated (n = 119)  and  FIV-unvaccinated  (n =  239)  cats  in  Australia.  FIV infection  status  was  assigned
by  considering  the  results  of all antibody  kits  in  concert  with  results  from  a commercially  available  PCR
assay  (FIV RealPCRTM). Two  lateral  ﬂow  immunochromatography  test  kits  (Witness  FeLV/FIV;  Anigen
Rapid  FIV/FeLV)  had  excellent  overall  sensitivity  (100%;  100%)  and  speciﬁcity  (98%;  100%)  and  could  dis-
cern the true  FIV  infection  status  of  cats, irrespective  of  FIV vaccination  history.  The  lateral  ﬂow  ELISAmmunochromatography
LISA
CR
ats
test  kit  (SNAP  FIV/FeLV  Combo)  could  not  determine  if  antibodies  detected  were  due  to  previous  FIV
vaccination,  natural  FIV  infection,  or both.  The  sensitivity  and  speciﬁcity  of  FIV  RealPCRTM for  detection
of  viral  and  proviral  nucleic  acid  was  92%  and  99%,  respectively.  These  results  will  potentially  change  the
way  veterinary  practitioners  screen  for  FIV  in  jurisdictions  where  FIV  vaccination  is  practiced,  especially
in shelter  scenarios  where  the  feasibility  of  mass  screening  is  impacted  by the  cost  of  testing.
© 2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
Feline immunodeﬁciency virus (FIV) is a retrovirus of the genus
entivirus. It was discovered in 1986 following investigation of an
mmunodeﬁciency syndrome in a household of cats in California,
SA [1] and shown subsequently to have worldwide distribution.
ealthy client-owned cat populations have been reported with
nfection rates of approximately 3% in Germany [2] and the USA
3], 6% in Canada [4] and the United Kingdom [5], 8% in Australia
6], 10% in New Zealand [7] and 23% in Japan [8]. The prevalence
f FIV infection is higher in entire male cats, castrated male cats
nd feral cats compared to the general client-owned domestic cat
opulation [3,6].
The FIV genome is comprised of three main structural genes,ag, pol and env, which encode internal structural proteins, viral
nzymes and envelope glycoproteins, respectively. Six distinct FIV
ubtypes (A to F) have been identiﬁed based on genetic diversity in
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/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
the variable V3–5 region of the env gene [9,10], while an additional
subtype has been detected in New Zealand cats [11]. Subtypes A,
B and C are most commonly encountered worldwide [12], with
subtype A predominant in Australia [9,13]. Nucleotide sequence
may  vary up to 15% within a subtype and up to 38% between sub-
types [14,15]. Subtyping of FIV infections in each geographic area
is important as the sole commercially available FIV vaccine con-
tains only subtypes A and D1 and heterologous challenge may  lower
vaccine effectiveness [16,17], although subtyping alone appears
insufﬁcient to predict vaccine performance [18].
Regardless of the FIV subtype, point-of-care testing to identify
antibodies directed against FIV has been the mainstay of diagnostic
testing for over 20 years, supplemented by western blot analysis
and virus isolation in research settings. Point-of-care test kits are
inexpensive, easy to use and reliably diagnose FIV infection in FIV-
unvaccinated cats [19]. There is variation between commercially
available antibody test kits in the methodology and target viral
antigen for antibody detection. SNAP FIV/FeLV Combo2 is a lateral
1 Fel-O-Vax® FIV, Boehringer Ingelheim, Fort Dodge, IA, USA.
2 IDEXX Laboratories, Westbrook, ME,  USA.
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Fig. 1. Schematic of FIV emphasising the differ
Table 1
Summary of the antibodies detected using four different point-of-care FIV antibody
test kits.
FIV antibody detection kit FIV target antigen
p15 p24 gp40
SNAP FIV/FeLV Combo (Australia, NZ, North America)
SNAP FIV/FeLV Combo Plus (Europe)a
Witness FeLV/FIV
ﬂ
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a Not used in this study, but used by Hartmann et al. [19].
ow enzyme-linked immunosorbent assay (ELISA) kit that detects
ntibodies to p15 (matrix protein) and p24 (capsid protein),
itness FeLV/FIV3 is a lateral ﬂow immunochromatography kit
hat detects antibodies to gp40 (transmembrane glycoprotein),
hile Anigen Rapid FIV/FeLV4 is a lateral ﬂow immunochromatog-
aphy kit that detects antibodies to p24 and gp40 (Fig. 1 and
able 1). SNAP FIV/FeLV Combo Plus, available only in Europe,
s a lateral ﬂow ELISA kit that detects antibodies to p15, p24
nd gp40. Published sensitivity and speciﬁcity of each test kit in
IV-unvaccinated cats are 94% and 100% for SNAP FIV/FeLV Combo
https://www.idexx.com/ﬁles/small-animal-health/products-and-
ervices/snap-products/snap-ﬁv-felv-combo/snap-combo-test-
ccuracy.pdf),[35] 100% and 100% for SNAP FIV/FeLV Combo Plus,
5% and 99% for Witness FeLV/FIV [19], and 89% and 100% for
nigen Rapid FIV/FeLV [20].
The introduction of the FIV vaccine in 2002 complicated FIV
iagnosis because vaccination was reported to result in the produc-
ion of antibodies to FIV indistinguishable from those produced in
esponse to natural infection [21]. Consequently, for FIV-vaccinated
ats and cats of unknown vaccination status, FIV diagnostics shifted
owards molecular methods such as nucleic acid ampliﬁcation
22,23]. Some studies have also explored alternative methods for
IV diagnosis with excellent results, such as a discriminatory ELISA
ased on antibody response to two different FIV antigens [24,25],
nd by calculating the CD4:CD8low T-lymphocyte ratio [26].In this study, we reappraised the assertion that point-of-care
its are unable to distinguish antibodies produced following FIV
accination from antibodies produced in response to natural FIV
3 Zoetis Animal Health, Lyon, France.
4 BioNote, Gyeonggi-do, Korea.ent target antigens for antibody testing.
infection, and therefore are unable to determine the true FIV
infection status of FIV-vaccinated cats, using three commercially
available test kits.
2. Material and methods
2.1. Sample population
Cats with known FIV vaccination history were recruited through
veterinary clinics in Australia during 2013–2014, most commonly
at the same time as an annual health check or some routine proce-
dure (e.g. dental scaling and polishing). Very occasionally, cats were
sampled during hospitalisation for further work up of systemic
illness; however no FIV-infected cats would have been classiﬁed
as being in the feline-AIDS (FAIDS) phase of infection. Cats or
kittens were excluded from the study if they were less than six
months of age (due to the possibility of maternal antibodies being
present), had an unclear FIV vaccination history or had a known
FIV infection status (due to prior testing). Cats were included in the
‘FIV-vaccinated’ group if they had received one or more FIV vaccines
at any time in their life, regardless of whether or not the adminis-
tration of vaccine had been in accordance with the manufacturer’s
guidelines1. Cats were included in the ‘FIV-unvaccinated’ group if
they had never been vaccinated against FIV. Clinical records of all
patients from both groups were carefully interrogated to enforce
this inclusion criterion. Cases were recruited from veterinary prac-
tices servicing areas where the prevalence of FIV infection was
perceived to be high [27].
Animal ethics approval was  granted by the University of Sydney
(Approval number 5920).
2.2. Serological and molecular detection of FIV infection
Blood was  collected by the primary author using jugular
venipuncture and immediately aliquoted into three EDTA tubes
and stored at 4 ◦C. Testing for FIV antibodies was performed within
24 hours of blood collection5 with three commercially available
point-of-care kits tested concurrently, using whole blood from
the same EDTA tube, according to the manufacturer’s instructions.
The antibody kits tested were SNAP FIV/FeLV Combo2, Witness
FeLV/FIV3, and Anigen Rapid FIV/FeLV4 (Table 1). The antibody
results panel for each cat was digitally photographed at the time of
testing. Blood from this tube was also used for routine haematologic
5 Faculty of Veterinary Science, The University of Sydney, Sydney, NSW, Australia.
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Table  2
Determination of FIV infection status of cats in the study. Classiﬁcation of FIV status was based on the overall combination of results from (a) three commercially available
FIV  antibody test kits (SNAP FIV/FeLV Combo, Witness FeLV/FIV and Anigen Rapid FIV/FeLV) and FIV RealPCRTM testing. Additional testing (repeat FIV RealPCRTM testing,
PCR  testing using different primers and methodology and/or virus isolation) was pursued when the results panel was equally divided (two positive results, two  negative
results), when there was complete agreement between antibody results but disagreement with the FIV RealPCRTM result, and to conﬁrm FIV infection in FIV-vaccinated
cats.  + = positive, − = negative, NP = not performed. Red = FIV-infected, yellow = FIV-uninfected.
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xamination.6 The second EDTA tube was centrifuged within 6 h
f collection for 3 min  at 12,000 × g and the plasma transferred
o a plain tube using a sterile pipette. Plasma specimens and
DTA cell pellets were stored subsequently at −80 ◦C for conﬁrma-
ory testing of discrepant samples at a later time. The third EDTA
ube was sent for FIV nucleic acid ampliﬁcation (FIV RealPCRTM),7
 commercially available PCR assay targeting a conserved gag
egion in both viral RNA (using cDNA following a reverse tran-
cription step) and proviral DNA. FIV subtype was determined
n infected cats using subtype speciﬁc primer pairs for subtypes
, B, D and F (http://www.idexx.com.au/pdf/en au/smallanimal/
ducation/realpcr-test-for-ﬁv.pdf) [34].
.3. Deﬁning FIV infection status (Table 2)
At the beginning of the study FIV RealPCRTM testing was used
s the ‘gold standard’ for FIV diagnosis, with a published sensitivity
nd speciﬁcity of 94% and 94% [28]. As the study progressed, how-
ver, it became clear that two of the antibody detection kits were
ble to determine the true FIV infection status of cats, irrespective
f FIV vaccination history. In light of this ﬁnding, revised deﬁnitions
or ‘FIV-infected’ and ‘FIV-uninfected’ were employed, which con-
idered results from all three antibody kits in concert with the FIV
ealPCRTM result. Where there was complete agreement between
he three antibody kits and the FIV RealPCRTM result (either all
6 Veterinary Pathology Diagnostic Services, The University of Sydney, Sydney,
SW, Australia.
7 IDEXX Laboratories, East Brisbane, Queensland, Australia.-
negative or all positive), assigning a given cat’s FIV infection status
was straightforward. Where two  of the three antibody kits matched
the FIV RealPCRTM result (i.e. three out of four results were in
agreement), FIV infection status was assigned and it was  assumed
the conﬂicting antibody kit was  a false-positive or false-negative
result. Where all three antibody kits tested negative and the FIV
RealPCRTM result was positive, FIV RealPCRTM testing was repeated
using either stored sample or a fresh blood specimen (collected at
a second venipuncture), and the second FIV RealPCRTM result was
taken as being deﬁnitive. Where all three antibody kits tested pos-
itive and the FIV RealPCRTM result was  negative, PCR testing was
repeated at a second commercial laboratory using stored sample
and a methodologically distinct assay (www.gribblesvets.com.au/
index.php/download ﬁle/view/90/142/)8 [37] and FIV RealPCRTM
testing was repeated using fresh blood collected at several time
points over 12–18 months. For such cats, additional fresh blood
was also collected into a heparinised tube and sent refrigerated to
a third laboratory for virus isolation (VI).9 The VI result was  consid-
ered deﬁnitive. The same additional testing was also undertaken
to conﬁrm FIV infection in FIV-vaccinated cats that tested positive
with all three antibody kits as well as FIV RealPCRTM, i.e. vaccination
‘failures’. Where there were two positive and two  negative results,
regardless of which tests were positive, additional blood was col-
lected into a heparanised tube and sent refrigerated to a fourth
laboratory for VI,10 with the VI result taken as being deﬁnitive.
8 Gribbles Veterinary Pathology, Melbourne, Victoria, Australia.
9 Yamamoto Laboratory, The University of Florida, Gainesville, FL, USA.
10 Veterinary Diagnostic Services, The University of Glasgow, Scotland, UK.
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Table  3
Summary of results from FIV-vaccinated cats (n = 119), highlighting general trends as well as discrepant results. Only 2/3 FIV-vaccinated/FIV-infected, initially FIV RealPCRTM
positive, cats had virus isolation performed. Both FIV-vaccinated/FIV-infected, initially FIV RealPCRTM negative, cats had blood sent to a second commercial laboratory for
conﬁrmatory PCR testing. Cat #102 was negative with repeat FIV RealPCRTM testing as well as PCR testing at the second commercial laboratory . Discordant cats were re-tested
at  a later date using thawed plasma stored at −80 ◦C. + = positive, − = negative, NP = not performed.
FIV-vaccinated/FIV-uninfected (n = 107) + - - - NP
FIV-vaccinated/FIV -infe cted (n = 3) + + + + + (2/3)
FIV-vaccinated/FIV infected (n = 2) + + + - + (2/2)
FIV-vaccinated/FIV -un infected discordant cats (n = 7)
Cat #97 + Faint + - - - 
Cat #173 + Faint + - - NP13
Cat #340 + Faint + - - - 
Cat #341 + Faint + - - - 
Cat #345 + Faint + - - - 
Cat #350 + Faint + - - - 
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When determining the results of the antibody test kits, even
 faint band or spot was subjectively recorded as a ‘faint posi-
ive’ result. Although the manufacturer’s instructions for Witness
eLV/FIV and Anigen Rapid FIV/FeLV contain no guidelines for inter-
reting faint results, instructions for SNAP FIV/FeLV Combo advise
hat any colour development in the FIV sample spot should be
onsidered signiﬁcant (https://www.idexx.com/resource-library/
mallanimal/snap-combo-package-insert-en.pdf) [36]. Antibody
esting was repeated using stored plasma thawed from −80 ◦C
here there was disagreement between all three antibody kits and
he FIV RealPCRTM result, where there were two positive and two
egative results, and where a ‘faint positive’ result was  recorded
sing any of the antibody kits.
For the purpose of this study, SNAP FIV/FeLV Combo, Wit-
ess FeLV/FIV and Anigen Rapid FIV/FeLV are antibody test kits
old for the sole purpose of diagnosing FIV infection. Therefore,
y deﬁnition, a positive antibody test result in a FIV-uninfected
at, regardless of FIV vaccination history, was considered a false-
ositive result. Conversely, a negative antibody test result in a
IV-uninfected cat, regardless of FIV vaccination history, was  con-
idered a true-negative result.
.4. Statistical analysis
Numerical analyses were performed using a commercial pro-
ramme  (Genstat 16th Edition).11 Statistical signiﬁcance was
onsidered at P < 0.05 and 95% conﬁdence intervals (CI) were cal-
ulated using Microsoft Excel.12 Fisher’s exact test was used to
nvestigate whether SNAP FIV/FeLV Combo and Witness FeLV/FIV
alse-positive results were more common in FIV-vaccinated cats
11 GenStat 16th Edition for Windows, VSN International, Hemel Hempstead, United
ingdom.
12 Microsoft Excel 2010 for Windows, Microsoft, Redmond, WA,  USA.- - + NP
than FIV-unvaccinated cats by comparing false-positive and true-
negative results. Fisher’s exact tests were also used to examine
whether ‘faint positive’ results with any of the three antibody test
kits was  associated with FIV infection status. A two-sample t-test
was used to investigate whether there was  a correlation between
time since last FIV vaccination and false-positive antibody results
recorded with Witness FeLV/FIV in the FIV-vaccinated group.
3. Results
3.1. Sample population
Blood samples were obtained from 358 client-owned cats
recruited from 12 veterinary clinics distributed over four states
of Australia (New South Wales, Victoria, Queensland and South
Australia) (Online Supplement 1).
A total of 119 FIV-vaccinated cats were recruited, ranging from
six months to 18 years (median 7 years; interquartile range [IQR]
5–10 years). These cats comprised 66 castrated males and 53
spayed females. Most were domestic crossbred cats (103/119;
87%); the remainder comprising a range of pedigree breeds. Most
cats in this cohort (109/119; 92%) had received three primary FIV
vaccinations, two to four weeks apart (i.e. the protocol recom-
mended by the vaccine manufacturer), and three or more annual
FIV vaccinations before being sampled. For these 109 cats sampling
took place between 2 and 462 days following their last FIV vaccina-
tion (median 237 days; IQR 152–317 days), with 10/109 (9%) cats
sampled within eight weeks of their last annual FIV vaccination.
Seven cats (out of 119) were considered overdue for their annual FIV
vaccination (more than 15 months since last vaccination; median
5.4 years, range 3–7 years), and three cats were overdue for their
second or third primary FIV vaccination (by 46 days, 74 days and 3
years).
A total of 239 FIV-unvaccinated cats were recruited, ranging
from 2 to 20 years (median 7 years; IQR 6–10 years). These cats
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Fig. 2. Photograph of test kit results from a FIV-vaccinated/FIV-infected cat, showing
three positive FIV antibody test kit results: (a) Anigen Rapid FIV/FeLV, (b) Witness
FeLV/FIV, and (c) SNAP FIV/FeLV Combo. For both immunochromatography kits the
top  strip is for FIV antibody testing and the bottom strip is for FeLV antigen testing.
One band in the FIV or FeLV strip indicates a negative result, while two  bands in the
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Fig. 3. Photograph of test kit results from a FIV-vaccinated/FIV-uninfected cat,
showing two negative FIV antibody test kit results: (a) Anigen Rapid FIV/FeLV, and
(b)  Witness FeLV/FIV; and one positive FIV antibody test kit result, (c) SNAP FIV/FeLV
Combo. For both immunochromatography kits the top strip is for FIV antibody test-
ing  and the bottom strip is for FeLV antigen testing. One band in the FIV or FeLVIV or FeLV strip indicates a positive result. For SNAP FIV/FeLV Combo, two  spots in
he displayed formation indicates a positive FIV result. This result was obtained in
/119 cats.
omprised 112 castrated males, 123 spayed females, and 4 entire
ales. Most were domestic crossbred cats (207/239; 87%); the
emainder comprising a range of pedigree breeds.
.2. Serological and molecular detection of FIV infection
.2.1. FIV-vaccinated cohort (n = 119, Tables 3 and 4)
All FIV-vaccinated cats (119/119) tested FIV positive using SNAP
IV/FeLV Combo. In contrast, only a small number of the 119 FIV-
accinated cats tested FIV positive using Witness FeLV/FIV (11 cats)
nd Anigen Rapid FIV/FeLV (5 cats) (Figs. 2 and 3).
All ﬁve cats that tested FIV positive using Anigen Rapid FIV/FeLV
lso tested FIV positive with the other two antibody kits. Initial FIV
ealPCRTM testing conﬁrmed 3/5 cats to be FIV-infected, which was
urther conﬁrmed by VI in 2 of these cats (one cat was unavail-
ble for further sampling). The remaining two cats were initially
egative with both FIV RealPCRTM and PCR testing at the sec-
nd laboratory. Subsequent resampling and re-testing, however,
ound both cats positive with FIV RealPCRTM and VI. Thus, all ﬁve
ats testing FIV positive using Anigen Rapid FIV/FeLV were truly
able 4
esults of three point-of-care FIV antibody test kits in FIV-vaccinated cats (n = 119).
onﬁdence intervals (95%) are given in brackets.
Test kit SNAP Combo Witness Anigen Rapid
True +ve 5 5 5
False +ve 114 6 0
True −ve 0 108 114
False −ve 0 0 0
Sensitivity (%) 5/5 = 100 5/5 = 100 5/5 = 100
Speciﬁcity (%) 0/114 = 0 108/114 = 95 114/114 = 100
(91–99)
PPV  (%) 5/119 = 4 5/11 = 45 5/5 = 100
(0–8) (16–75)
NPV (%) 0/0 = 0 108/108 = 100 114/114 = 100strip indicates a negative result, while two  bands in the FIV or FeLV strip indicates
a  positive result. For SNAP FIV/FeLV Combo, two  spots in the displayed formation
indicates a positive FIV result. This result was obtained in 108/119 cats.
FIV-infected. Of the ﬁve FIV-infected cats, three were castrated
males and two were spayed females.
The six cats that tested FIV positive with SNAP FIV/FeLV Combo
and Witness FeLV/FIV, but FIV negative with Anigen Rapid FIV/FeLV
and FIV RealPCRTM, were considered to be FIV-uninfected based
on VI results (i.e. the positive antibody kit results were false-
positives).13 Another FIV-vaccinated cat had FIV RealPCRTM testing
repeated due to possible contamination in the PCR facility; this cat,
which initially was FIV RealPCRTM positive, subsequently tested
FIV RealPCRTM negative and was  ultimately considered to be FIV-
uninfected.
No false-negative FIV results were recorded with any of the
antibody kits.
3.2.2. FIV-unvaccinated cohort (n = 239, Tables 5 and 6)
In this group of FIV-unvaccinated cats, 21 cats tested FIV positive
with all three antibody kits and were conﬁrmed to be FIV-infected
with FIV RealPCRTM testing. Of 21 FIV-infected cats, 15 were male
(14 castrated, one entire) and 6 were spayed females.
Of the remaining 218 FIV-uninfected cats in this group, most
(212/218) tested FIV negative with all three antibody kits. Six false-
positive FIV results were recorded using SNAP FIV/FeLV Combo,
one false-positive was  recorded using Witness FeLV/FIV, while no
false-positive results were recorded using Anigen Rapid FIV/FeLV.
One FIV-uninfected cat in this group (cat #305) tested FIV posi-
tive with both SNAP FIV/FeLV Combo and Witness FeLV/FIV, but FIV
negative with Anigen Rapid FIV/FeLV and FIV RealPCRTM; VI was
subsequently performed and conﬁrmed the negative FIV status.Three cats tested FIV negative with all three antibody kits but
initially positive with FIV RealPCRTM with varying cycle thresh-
old (CT) values: cat #126 tested positive for subtype A (CT 32), cat
13 13Only 5/6 cats had VI performed due to the unfortunate death (unrelated to
this study) of one of the cats.
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Table  5
Summary of results from FIV-unvaccinated cats (n = 239), highlighting general trends as well as discrepant results. Cat #126, cat #259 and cat #277 were negative with repeat
FIV  RealPCRTM testing. Discordant cats were re-tested at a later date using thawed plasma stored at −80 ◦C. + = positive, − = negative, NP = not performed.
FIV-unvaccinated/FIV-uninfected (n = 209) ---- NP
FIV-unvaccinated/FIV-infected (n = 21) + + + + NP
FIV-unvaccinated/FIV-uninfected discordant cats (n = 9)
Cat #60 Faint + - - - NP
Cat #263 Faint +  -  -  -  NP
Cat #280 Faint +  -  -  - NP
Cat #326 Faint +  -  -  -  NP
Cat #335 +  -  -  -  NP
Cat #305 + Faint +  -  -  - 
Cat #126 --- + NP
Cat #259 --- + NP
- 
Category SNAP  Combo Witness Anigen  Rapid PCR (inial) Virus isoIaon
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259 subtype F (CT 39) and cat #277 subtype D (CT 32). Repeat
IV RealPCRTM testing found all three cats to be FIV-uninfected and
resumably there was contamination at the PCR facility.
No false-negative FIV results were recorded with any of the
ntibody kits.
.2.3. Combined FIV-vaccinated and FIV-unvaccinated cohorts
n = 358, Table 7)
In total there were 120 false-positive FIV results recorded with
NAP FIV/FeLV Combo, seven false-positive FIV results recorded
ith Witness FeLV/FIV, and no false-positive FIV results recorded
ith Anigen Rapid FIV/FeLV. False-positive FIV results were signiﬁ-
antly more common in FIV-vaccinated cats than FIV-unvaccinated
ats for both SNAP FIV/FeLV Combo (114/120; 95%; P < 0.001) and
itness FeLV/FIV (6/7; 86%; P = 0.007). For Witness FeLV/FIV 10/33
30%) positive results were recorded as ‘faint positives’, while 7/146
5%) positive SNAP FIV/FeLV Combo and 7/26 (27%) positive Anigen
apid FIV/FeLV results were recorded as ‘faint positives’. ‘Faint pos-
tive’ results with Witness FeLV/FIV were strongly associated with
bsence of FIV infection and thus likely to be false-positive results
P < 0.001); only 3/26 FIV-infected cats recorded a ‘faint positive’
able 6
esults of three point-of-care FIV antibody test kits in FIV-unvaccinated cats
n  = 239). Conﬁdence intervals (95%) are given in brackets.
Test kit SNAP Combo Witness Anigen Rapid
True +ve 21 21 21
False +ve 6 1 0
True −ve 212 217 218
False −ve 0 0 0
Sensitivity (%) 21/21 = 100 21/21 = 100 21/21 = 100
Speciﬁcity (%) 212/218 = 97 217/218 = 100 218/218 = 100
(95–99) (99–100)
PPV (%) 21/27 = 78 21/22 = 95 21/21 = 100
(62–93) (87–100)
NPV (%) 212/212 = 100 217/217 = 100 218/218 = 100-- + NP
result with Witness FeLV/FIV, and 7/7 (100%) of false-positive Wit-
ness FeLV/FIV results were recorded as ‘faint positives’. There was
no association between ‘faint positive’ results and absence of FIV
infection (i.e. false-positive results) for either the SNAP FIV/FeLV
Combo or Anigen Rapid FIV/FeLV kit (P = 1.000 for both). Time
between last FIV vaccination and sampling was not a risk factor
for false-positive FIV results with Witness FeLV/FIV (P = 0.82 with
outliers [more than 15 months since last vaccination] removed);
only 1/11 recently vaccinated cats (8 weeks or less since last FIV
vaccination, cat #173) tested false-positive with Witness FIV/FeLV.
The other ﬁve false-positive FIV results with Witness FeLV/FIV in
vaccinated cats were recorded 139, 196, 259, 337 and 354 days
after last FIV vaccination. All 6 FIV-vaccinated cats that had a false-
positive FIV result with Witness FeLV/FIV had a ’faint positive’ result
recorded.
Discrepant samples that underwent repeat antibody testing
with stored plasma thawed from −80 ◦C recorded almost identical
antibody results as fresh whole blood tested initially (27 samples
re-tested using 81 antibody test kits with 80/81 [99%] agreement).
Based on this study’s deﬁnition for FIV positivity (Table 2), and
considering only the initial FIV RealPCRTM result, molecular detec-
tion of FIV using RealPCRTM testing produced four false-positive
and two  false-negative results, giving a sensitivity of 92% (95% CI
82.1 to 100) and speciﬁcity of 99% (95% CI 97.7 to 99.9). One false-
positive result and the two false-negative results were from the
FIV-vaccinated group, while three false-positive results were from
the FIV-unvaccinated group. Repeat FIV RealPCRTM testing, either
using the original sample or a subsequent sample, was  able to cor-
rectly assign FIV status in all six cats. Subtyping results for the
26 FIV-infected cats are given in Table 8, and CT values are avail-
able online (Online Supplement 2). Two subtypes were identiﬁed
in almost half of FIV-infected cats (11/26 cats; 42%). Infection with
FIV subtype A was identiﬁed most commonly (22/26 cats; 85%),
followed by subtype F (12/26 cats; 35%) and subtype D (3/26 cats;
12%). Subtype B was not identiﬁed in any FIV-infected cats.
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Table  7
Combined results of three point-of-care FIV antibody test kits in FIV-vaccinated and
FIV-unvaccinated cats (n = 358). Note that this composite population was  strongly
biased by FIV-vaccinated cats (119/358; 33%). In practice, the percentage of vacci-
nated cats in an area will be heavily dependent on the vaccination protocols of local
veterinary clinics and may differ considerably from this value. Conﬁdence intervals
(95%) are given in brackets.
Test kit SNAP Combo Witness Anigen Rapid
True +ve 26 26 26
False +ve 120 7 0
True −ve 212 325 332
False −ve 0 0 0
Sensitivity (%) 26/26 = 100 26/26 = 100 26/26 = 100
Speciﬁcity (%) 212/332 = 64 325/332 = 98 332/332 = 100
(59–69) (96–99)
PPV (%) 26/146 = 18 26/33 = 79 26/26 = 100
(12–24) (65–93)
NPV (%) 212/212 = 100 325/325 = 100 332/332 = 100
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. Discussion
FIV infection was reliably diagnosed in FIV-vaccinated and
IV-unvaccinated cats using two inexpensive, fast, simple to use
ntibody detection kits made by different manufacturers (Witness
eLV/FIV and Anigen Rapid FIV/FeLV). This ﬁnding will facilitate
eterinary practices and shelters to quickly and conﬁdently deter-
ine the FIV infection status of cats, regardless of FIV vaccination
istory, thereby providing a less expensive option than testing
sing serology and conﬁrmatory testing with a PCR assay.
Immediately following the release of the FIV vaccine in the USA,
ne study demonstrated that FIV-vaccinated cats tested FIV pos-
tive using SNAP FIV/FeLV Combo as early as three weeks after
he second primary FIV vaccine, and that vaccinated cats would
emain seropositive for at least 12 months post vaccination [21].
his ﬁnding was recapitulated when another group found that 26
IV-vaccinated cats all tested FIV positive using SNAP FIV/FeLV
ombo within three weeks of the third primary FIV vaccine. In the
ame study, all 26 FIV-vaccinated cats also tested positive using
 microwell plate ELISA (Petchek FIV, IDEXX Laboratories) at 14
eeks after the third primary FIV vaccine [29]. At this time, reg-
stration restrictions limited the availability of other FIV antibody
est kits for use in these studies in North America. Later research
ound it was possible to accurately distinguish FIV-vaccinated from
IV-infected cats using a discriminatory ELISA that considered anti-
ody response to both formalin-treated whole FIV and a synthetic
ransmembrane (TM) peptide [24,25]. Recently, investigation using
he CD4:CD8low T-lymphocyte ratio to differentiate between FIV-
accinated and FIV-infected cats showed promise [26]. However,
oth of these methods are currently unavailable to veterinarians in
ractice. To our knowledge, the current study is the ﬁrst to exten-
ively investigate the performance of Witness FeLV/FIV and Anigen
apid FIV/FeLV antibody test kits in FIV-vaccinated cats.
The Witness FeLV/FIV and Anigen Rapid FIV/FeLV antibody
its demonstrated excellent sensitivity and speciﬁcity using our
able 8
ubtyping results from FIV RealPCRTM testing. Primers pairs for FIV subtypes A, B, D
nd F were included in the PCR reaction.
FIV subtype Frequency
FIV A only 14/26 = 54%
FIV B only 0
FIV D only 0
FIV F only 1/26 = 4%
FIV A/F 8/26 = 31%
FIV D/F 3/26 = 12%biology and Infectious Diseases 42 (2015) 43–52 49
deﬁnition for FIV positivity, even in a study population where 33%
of cats (119/358) were FIV-vaccinated. The cause of the seven false-
positive FIV results with the Witness FeLV/FIV kit may  be a lower
threshold for antibody detection compared to the Anigen Rapid
FIV/FeLV kit, as most (6/7) were in FIV-vaccinated cats. Presumably
there is a low titre of antibody to gp40 following FIV vaccination
that is detectable in a small subset of cats using Witness FeLV/FIV,
manifesting as a ‘faint positive’ test result. In another diagnostic
study, faint results were classiﬁed as equivocal if the colour change
for the sample spot was less than 50% of the positive control, as
determined by a plate reader [30].
It was not possible to attribute false-positive FIV results with
the Witness FeLV/FIV kit as a result of recent FIV vaccination;
false-positive results actually occurred most frequently in cats not
recently vaccinated (5/6 cats had not been vaccinated for at least
four months). In contrast, a recent abstract reported a high pro-
portion of false-positive FIV results using the Witness FeLV/FIV
kit in experimentally vaccinated kittens in a research colony. For
example, ﬁve weeks after FIV vaccination 14/19 (74%) tested FIV
positive, while by 34 weeks after vaccination all kittens tested
FIV negative [31]. Clearly, further research needs to be conducted
to better understand humoral immune response following FIV
vaccination, in particular the time course of antibody production
directed against gp40.
A potential algorithm for FIV screening in a group of cats of
known or unknown FIV vaccination history is (i) start with Anigen
Rapid FIV/FeLV or Witness FeLV/FIV testing; (ii) repeat testing with
the other antibody kit if a positive FIV test result is encountered;
(iii) pursue further conﬁrmatory testing such as PCR (or VI) for cats
only when there is disagreement between the two test kits or a high
index of suspicion for FIV remains due to the clinical presentation,
such as sequential opportunistic infections or wasting syndromes
(Fig. 4). If results of the two  immunochromatography kits were con-
sidered together there was agreement in 351/358 (98%) of cats,
with FIV RealPCRTM testing and VI required to clarify the FIV sta-
tus of only seven cats. In a shelter environment, where resources
are limited and vaccination histories are commonly unavailable,
this algorithm would result in a substantial cost saving and could
inﬂuence whether shelters can afford to test for FIV.
All FIV-infected and FIV-vaccinated cats tested FIV positive using
SNAP FIV/FeLV Combo. Critically, this antibody kit was  not able to
distinguish the 114 FIV-vaccinated/FIV-uninfected cats from the
ﬁve FIV-vaccinated/FIV-infected cats, in agreement with previous
reports. The FIV-vaccinated group included cats that had not been
vaccinated for up to seven years, demonstrating that vaccination
induces production of antibodies which are detectable using this
kit for an extended period of time. A previous study found 100%
of cats tested (n = 5) still had detectable FIV antibodies over two
years after initial vaccination [29]. In adult cats of unknown FIV-
vaccination status, a positive FIV test result with SNAP FIV/FeLV
Combo could therefore indicate FIV vaccination, FIV infection, or
both. A major consequence of this uncertainty is in a shelter setting
where incorrect diagnosis of FIV infection can result in euthana-
sia [22,32]. It should be noted that the reported speciﬁcity of
SNAP FIV/FeLV Combo for the entire study population (64%; 95% CI
59–69%; Table 6) was  directly affected by the inclusion of 119 FIV-
vaccinated cats to create a composite population of FIV-vaccinated
(119/358; 33%) and FIV-unvaccinated (239/358; 67%) cats. As the
percentage of FIV-vaccinated cats in a population decreases from
33%, the speciﬁcity of SNAP FIV/FeLV Combo will progressively
increase (and vice versa). In practice, the percentage of vaccinated
cats in an area will be heavily dependent on the vaccination proto-
cols of local veterinary clinics and may  differ considerably from the
33% of this study cohort. The performance of SNAP FIV/FeLV Combo
was comparable to the performance of the two immunochromatog-
raphy test kits in FIV-unvaccinated cats.
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Fig. 4. Suggested algorithm for diagnosis of FIV infection. If there is the possibility of recent FIV infection, re-testing is recommended due to delays in seroconversion and
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Fel-O-Vax® FIV vaccine contains formalin-inactivated whole
irus and infected Fet-J cells [33]. One possible explanation for the
ariation in results between the ELISA-based kit (SNAP FIV/FeLV
ombo) and immunochromatography kits (Witness FeLV/FIV and
nigen Rapid FIV/FeLV) in FIV-vaccinated cats is that relevant
ntigenic determinants of p15 may  be well preserved in the
ormalin-ﬁxed vaccine, whereas vaccine production may  render
24 and gp40 less persistently immunogenic. This would result
n the production of a high titre of host antibodies to p15 follow-
ng FIV vaccination, indistinguishable from antibodies produced
gainst p15 in response to natural FIV infection, but lower titres,
ess persistent titres, or even no production of antibodies to p24 or
p40. A similar hypothesis was suggested by the researchers who
eveloped a discriminatory ELISA measuring antibody response to
wo different FIV antigens, formalin-treated whole FIV and a syn-
hetic TM peptide, the latter which may  closely resemble the gp40
apture antigen used in the Witness FeLV/FIV antibody test kit. This
roup, however, was unable to distinguish FIV-vaccinated from FIV-
nfected cats using only one type of antigen. On further review, this
nability to distinguish FIV vaccination from FIV infection may  haveformed at least 8 weeks later for antibody testing and 4 weeks later for PCR testing
 for diagnostic samples in Australia.
been a consequence of including results from 16 recently infected
cats that when ﬁrst tested, only had low levels of detectable anti-
bodies to gp40, but when sampled 3–4 weeks later had much higher
antibody responses to gp40 [24]. There are major methodological
differences between western blot, ELISA and immunochromatog-
raphy which presumably lead to threshold differences in the level
of detection of antibodies for each method; these differences may
help explain variation in results between the current study and
earlier work conducted into antibody production in FIV-vaccinated
cats [21].
The results of the current study may suggest a useful reﬁnement
for point-of-care FIV antibody test kits in the future. By including
all three FIV antigens, but with p15 occupying a different spot or
line to p24 and gp40, it may  be possible to determine whether an
individual cat is (i) vaccinated and uninfected (p15 positive only);
(ii) infected (p15 and p24/gp40 positive); or (iii) unvaccinated and
uninfected (p15 and p24/gp40 negative). Currently, differentiation
of cats into these three groups is not possible using a single test
methodology, including nucleic acid ampliﬁcation, discriminating
ELISA [24,25] or considering the CD4:CD8low T-lymphocyte ratio
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26]. Such a reﬁnement to point-of-care antibody testing, how-
ver, should not be used as rationale for reducing frequency of FIV
accination in scenario (i) as the mechanism of vaccine induced
rotection involves both humoral and cell-mediated immunity
33].
The accuracy of FIV RealPCRTM testing in the current study
as comparable to results for a group of FIV-unvaccinated cats
28]. Initially, false-negative PCR results were obtained from two
IV-vaccinated cats that tested positive with all antibody kits and
ater were proven to be FIV-infected by VI. However, serial samp-
ing of these two cats eventually resulted in positive results with
IV RealPCRTM, suggesting that the initial viraemia was  below the
imit of detection for the assay. Interestingly, both of these cats
lso initially tested negative using a methodologically distinct PCR
ssay at a second commercial laboratory. False-positive results with
ealPCRTM were produced in one FIV-vaccinated cat and three FIV-
nvaccinated cats; retesting of these samples produced negative
esults. False-positive PCR results are usually thought to occur as a
esult of contamination during testing.
. Conclusion
Two point-of-care FIV antibody test kits (Witness FeLV/FIV and
nigen Rapid FIV/FeLV) could reliably identify natural FIV infection
n client-owned cats in Australia, irrespective of their FIV vac-
ination history. Where FIV vaccination is practiced, there is an
dvantage to using these kits for initial screening of FIV infection,
articularly in shelters where large numbers of cats need to be
ssessed quickly and affordably and where vaccination history is
ften unknown. A third point-of-care FIV antibody test kit (SNAP
IV/FeLV Combo) was useful for conﬁrming a humoral response
o FIV vaccination, but could not distinguish FIV-vaccinated from
IV-infected cats. All three antibody detection kits gave compara-
le and highly accurate results in determining FIV infection status
n FIV-unvaccinated cats.
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